source
- Neurocrine launches new safety study after another death linked to Prader-Willi drug VykatNeurocrine Biosciences announced it will start a new study to evaluate dosing and safety of its rare disease drug Vykat in patients with Prader-Willi syndrome who have complex health issues. The m…
- Pfizer partners with Sciwind to launch GLP-1 obesity drug Ecnoglutide in ChinaPfizer is entering China's obesity market with a new GLP-1 drug, Ecnoglutide, in partnership with Sciwind Biosciences. The New York-based company secured mainland China licensing rights to the inj…